[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neoplasm-malignant\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neoplasm-malignant":265},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,48,133,159,181,207,235],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":36,"lastUpdatePostDateStruct":37,"startDateStruct":40,"completionDateStruct":42,"leadSponsor":44,"locationsCount":47},"100609019","phase-2-a-clinical-study-of-calderasib-mk-1084-in-people-with-advanced-solid-tumors-mk-1084-014-100609019",false,"NCT07209111","A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)","A Phase 2, Open-Label, Multicenter, Tumor-agnostic Study of MK-1084 as Monotherapy and in Combination With Cetuximab, in Participants With KRAS G12C-Mutant, Advanced Solid Tumors (KANDLELIT-014)","KANDLELIT-014","Inclusion Criteria:\n\nThe main inclusion criteria include but are not limited to the following:\n\n* Has locally advanced unresectable or metastatic solid tumor malignancy other than colorectal cancer and has progressed on, or following, standard of care systemic treatment\n* Has a tumor that demonstrates the presence of Kirsten rat sarcoma (KRAS) G12C mutation\n\nExclusion Criteria:\n\nThe main exclusion criteria include but are not limited to the following:\n\n* Has uncontrolled, significant cardiovascular disease or cerebrovascular disease\n* Has known additional malignancy that is progressing or has required active treatment within the past 3 years\n* Has known active central nervous system metastases and\u002For carcinomatous meningitis and\u002For primary brain tumors\n* Has active infection, other than those permitted per protocol, requiring systemic therapy\n* Has not adequately recovered from major surgery or has ongoing surgical complications","ALL","18 Years",{"count":20,"type":21},150,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Researchers want to learn if calderasib given alone or with cetuximab can treat certain advanced solid tumors in people with the KRAS G12C mutation.\n\nThe goals of this study are to learn:\n\n* How many people have the cancer respond (get smaller or go away) to calderasib alone or with cetuximab and how these responses compare\n* About the safety of calderasib alone or with cetuximab and if people tolerate the treatments.",[27],"Neoplasm Malignant",[29,30,31,32,33,34],"KRAS","NSCLC","CRC","Tumor-agnostic","Pan Tumor","KRAS G12C","RECRUITING","2026-06-17",{"date":38,"type":39},"2026-06-22","ACTUAL",{"date":41,"type":39},"2025-12-04",{"date":43,"type":21},"2032-04-09",{"name":45,"class":46},"Merck Sharp & Dohme LLC","INDUSTRY",61,{"id":49,"slug":50,"hasResults":11,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":59,"briefSummary":61,"conditions":62,"keywords":95,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":132},"100355699","phase-1-hsv-g207-in-children-with-recurrent-or-refractory-cerebellar-brain-tumors-100355699","NCT03911388","HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors","Phase 1 Trial of Engineered HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors","Inclusion Criteria:\n\n* Age ≥ 36 months and \\\u003C 22 years\n* Pathologically proven malignant cerebellar brain tumor (including medulloblastoma, glioblastoma multiforme, giant cell glioblastoma, anaplastic astrocytoma, primitive neuroectodermal tumor, ependymoma, atypical teratoid\u002Frhabdoid tumor, germ cell tumor, or other high-grade malignant tumor) which is progressive or recurrent despite standard care including surgery, radiotherapy, and\u002For chemotherapy. A pathologically proven secondary malignant cerebellar tumor without curative treatment options is eligible.\n* Lesion must be ≥ 1.0 cm ≤ 3.0 cm in diameter and surgically accessible as determined by MRI. Larger tumors may be surgically debulked and treated if ≤ 3.0 cm after debulking\n* Patients must have fully recovered from acute treatment related toxicities of all prior chemotherapy, immunotherapy or radiotherapy prior to entering this study.\n* Myelosuppressive chemotherapy: patients must have received their last dose at least 3 weeks prior (or at least 6 weeks if nitrosurea)\n* Investigational\u002FBiologic agents: patients must have recovered from any acute toxicities potentially related to the agent and received last dose ≥ 7 days prior to entering this study (this period must be extended beyond the time during which adverse events are known to occur for agents with known adverse events ≥ 7 days). For viral therapy, patients must have received viral therapy ≥ 3 months prior to study entry and have recovered from all acute toxicities potentially related to the agent.\n* Monoclonal antibodies: The patient must have received last dose ≥ 21 days prior.\n* Radiation: Patients must have received their last fraction of craniospinal radiation (\\>24 Gy) or total body irradiation ≥ 3 months prior to study entry. Patients must have received focal radiation to symptomatic metastatic sites or local palliative radiation ≥ 28 days prior to study entry.\n* Autologous bone marrow transplant: Patients must be ≥ 3 months since transplant prior to study entry.\n* Normal hematological, renal and liver function (absolute neutrophil count \\> 1000\u002Fmm3, platelets \\> 100,000\u002Fmm3, prothrombin time (PT) or partial thromboplastin time (PTT) \\\u003C 1.3 x control, creatinine within normal institutional limits OR creatinine clearance \\>60 mL\u002Fmin\u002F1.73 m2 for patients with creatinine levels above institutional normal, total bilirubin \\\u003C 1.5 mg\u002Fdl, transaminases \\\u003C 3 times above the upper limits of the institutional norm)\n* Patients \\\u003C 16 years, Modified Lansky performance score ≥ 60; patients ≥ 16 years, Karnofsky performance score ≥ 60\n* Patient life expectancy must be at least 8 weeks\n* Written informed consent in accordance with institutional and FDA guidelines must be obtained from patient or legal guardian\n\nExclusion Criteria:\n\n* Any treatment outside the allowable guidelines outlined in section 5.1.\n* Diffuse, widespread, abnormal tumor pattern involving 3 or more lobes of the brain\n* Acute infection, granulocytopenia or medical condition precluding surgery\n* Pregnant or lactating females\n* Diagnosis of encephalitis or CNS infection \\\u003C 3 months prior, or receiving ongoing treatment for encephalitis, CNS infection or multiple sclerosis\n* Tumor involvement which would require ventricular or brainstem inoculation or would require access through a ventricle in order to deliver treatment\n* Required steroid increase within 1 week prior to G207 inoculation or patients requiring \\>2 mg of dexamethasone daily\n* Known HIV seropositivity\n* Concurrent therapy with any drug active against HSV (acyclovir, valacyclovir, penciclovir, famciclovir, gancyclovir, foscarnet, cidofovir) or any immunosuppressive drug therapy (except dexamethasone or prednisone).\n* Other current malignancy\n* Concurrent anticancer or investigational drug","3 Years","21 Years",{"count":58,"type":21},24,[60],"PHASE1","This study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumor. The safety of combining G207 with a single low dose of radiation, designed to enhance virus replication, tumor cell killing, and an anti-tumor immune response, will also be tested.\n\nFunding Source- FDA OOPD",[63,64,65,66,67,68,69,70,71,72,73,74,75,76,27,77,78,79,80,81,82,83,84,85,86,87,88,89,90,91,92,93,94],"Neoplasms, Brain","Glioblastoma Multiforme","Glioblastoma of Cerebellum","Neoplasms","Astrocytoma","Astrocytoma, Cerebellar","Neuroectodermal Tumors","Neuroectodermal Tumors, Primitive","Cerebellar PNET, Childhood","Cerebellar Neoplasms","Cerebellar Neoplasms, Primary","Cerebellar Neoplasm, Malignant","Cerebellar Neoplasm Malignant Primary","Neoplasm Metastases","Neoplasms, Neuroepithelial","Neoplasms, Germ Cell and Embryonal","Neoplasms by Histologic Type","Neoplasms, Glandular and Epithelial","Neoplasms, Nerve Tissue","Central Nervous System Neoplasms, Primary","Central Nervous System Neoplasms, Malignant","Nervous System Neoplasms","Neoplasms by Site","Brain Diseases","Central Nervous System Diseases","Nervous System Diseases","Medulloblastoma Recurrent","HSV","Virus","Pediatric Brain Tumor","Nervous System Cancer","Primitive Neuroectodermal Tumor (PNET) of Cerebellum",[96,97,64,98,99,100,101,102,103,104,105,106,107,108,109,110,66,111,112,113,114,115,116,117,118,91,90,119,120,121],"Brain Tumor, Recurrent","Glioma","Gliosarcoma","Medulloblastoma","Anaplastic Astrocytoma","Oligodendroglioma","Rhabdoid Tumor","Ependymoma","Germ Cell Tumor","Choroid Plexus Carcinoma","Cerebral Primitive Neuroectodermal Tumor","Giant Cell Glioblastoma","Atypical teratoid\u002Frhabdoid tumor","Secondary Malignant Cerebellar Tumor","Embryonal Tumor","Oncolytic Virus Therapy","Virotherapy, Oncolytic","Immunotherapy","Central Nervous System Agents","Antineoplastic Agents","Pediatric","Pediatrics","Oncolytic","Herpes Virus","G207","Oncolytic Herpes Virus","2026-05-13",{"date":124,"type":39},"2026-05-15",{"date":126,"type":39},"2019-09-12",{"date":128,"type":21},"2027-09-01",{"name":130,"class":131},"M.D. Anderson Cancer Center","OTHER",3,{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":137,"acronym":138,"eligibilityCriteria":139,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":140,"targetDuration":4,"studyType":22,"phases":142,"briefSummary":144,"conditions":145,"keywords":146,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":149,"lastUpdatePostDateStruct":150,"startDateStruct":152,"completionDateStruct":154,"leadSponsor":156,"locationsCount":158},"100576219","development-of-preclinical-models-derived-from-tumors-with-a-molecular-abnormality-of-interest-to-test-their-sensitivity-to-new-anti-tumor-therapies-100576219","NCT06782451","Development of Preclinical Models Derived From Tumors With a Molecular Abnormality of Interest to Test Their Sensitivity to New Anti-tumor Therapies.","DST","Inclusion Criteria:\n\n* Age 18 years or older.\n* Patient for whom at least one mutation deemed of interest by the investigator has been identified.\n* Patient with a malignant tumor at a locally advanced or metastatic stage, for whom a tissue tumor sample (via surgery, radiology, or endoscopy) is scheduled as part of their standard care.\n* Tumor volume deemed sufficient by the physician to ensure an adequate amount of material for analysis by the pathologist and the transfer of a part of the tumor sample to the Laboratory of Translational Research in Oncology for the study.\n* INR \\\u003C 1.5; Platelets \\> 50,000\u002FμL.\n* Patient who has been informed of the study and has signed the informed consent form.\n* Patient affiliated with a social security insurance.\n\nExclusion Criteria:\n\n* Patient with multiple primary malignant tumors.\n* Patient with a known HIV, Hepatitis C, or Hepatitis B infection.\n* Patient on:\n\n  * Clopidogrel (hydrogensulfate) or Prasugrel (hydrochloride) or Ticlopidine (hydrochloride) with no possibility of suspension for 5 days,\n  * Low molecular weight heparin with no possibility of dose suspension before the procedure,\n  * Fondaparinux with no possibility of suspension,\n  * Abciximab with no possibility of suspension for 24 hours and aPTT \\\u003C 50s and ACT \\\u003C 150s,\n  * Eptifibatide or Tirofiban Hydrochloride Monohydrate or Argatroban with no possibility of suspension 4 hours before the procedure,\n  * Bivalirudin with no possibility of suspension 2-3 hours if CrCL \\>50 mL\u002Fmin or 3-5 hours if CrCL \\\u003C50 mL\u002Fmin before the procedure,\n  * Dabigatran etexilate with no possibility of suspension 2-3 days if CrCL \\>50 mL\u002Fmin or 3-5 days if CrCL \\\u003C50 mL\u002Fmin before the procedure.\n* Patient considered vulnerable; vulnerable persons are defined in articles L1121-5 to L1121-8:\n\n  * Pregnant women, parturients, and breastfeeding mothers,\n  * Individuals deprived of their liberty by a judicial or administrative decision, individuals hospitalized without consent under articles L. 3212-1 and L. 3213-1 who do not fall under the provisions of article L. 1121-8, and individuals admitted to a healthcare or social facility for reasons other than research,\n  * Adults under legal protection or unable to express their consent.",{"count":141,"type":21},50,[143],"NA","This study aims to collect tumor samples from patients carrying a mutation of interest to develop a cell culture technique for \"spheroids.\n\nThe goal is to use these spheroids to model responses to anticancer treatments. Various therapeutic molecules can be tested on these spheroids, enabling the evaluation of the potential of new molecules or the activity of existing ones specifically on the tumor (bearing the mutation of interest) from which the spheroid was developed.\n\nTumor samples will be collected as part of biopsies or surgeries conducted during routine patient care.",[27],[147,148],"Spheroids","Preclinic models","2025-09-24",{"date":151,"type":39},"2025-09-29",{"date":153,"type":39},"2025-05-02",{"date":155,"type":21},"2030-07-02",{"name":157,"class":131},"Centre Antoine Lacassagne",1,{"id":160,"slug":161,"hasResults":11,"nctId":162,"briefTitle":163,"officialTitle":163,"acronym":164,"eligibilityCriteria":165,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":166,"targetDuration":4,"studyType":22,"phases":168,"briefSummary":169,"conditions":170,"keywords":171,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":158},"100562684","study-on-the-contribution-of-the-genetic-tumor-profile-obtained-by-circulating-tumor-dna-analysis-in-the-multidisciplinary-molecular-biology-meeting-of-eastern-paca-100562684","NCT06606366","Study on the Contribution of the Genetic Tumor Profile Obtained by Circulating Tumor DNA Analysis in the Multidisciplinary Molecular Biology Meeting of Eastern PACA","TARGET","Inclusion Criteria:\n\n* Over 18 years old.\n* Advanced-stage malignant solid tumor managed in a non-curative context.\n* Patient eligible for Multidisciplinary molecular biology meeting with available archived tumor material (frozen or FFPE block, less than 5 years old) or a biopsiable tumor lesion.\n* Performance status of 0 or 1.\n* Patient able to read, write, and understand the French language.\n* Patient has read the information sheet and signed the informed consent.\n* Patient has social security coverage.\n\nExclusion Criteria:\n\n* Previous or concurrent cancer diagnosed or treated within the last 5 years, except for in situ carcinoma of the cervix, basal cell or squamous cell carcinoma of the skin, and adequately treated in situ carcinoma of the bladder.\n* Severe or uncontrolled systemic disease.\n* Any condition which, in the investigator's judgment (geographical, social, or psychological factors, etc.), makes the patient unable to comply with study follow-up and procedures.\n* Patient considered a vulnerable person; vulnerable persons are defined in Articles L1121-5 to L1121-8:\n\n  * Pregnant women, women in labor, and breastfeeding mothers,\n  * Persons deprived of liberty by judicial or administrative decision, individuals hospitalized without consent under Articles L. 3212-1 and L. 3213-1 who do not fall under the provisions of Article L. 1121-8,\n  * Persons admitted to a healthcare or social institution for reasons other than research,\n  * Adults unable to give their consent.",{"count":167,"type":21},238,[143],"This study will evaluate the diagnostic performance of liquid biopsy for identifying molecular abnormalities among patients managed by the Multidisciplinary Molecular Biology Meeting. The gold standard considered in this study is the solid biopsy.",[27],[172],"Liquid biopsy","2025-04-10",{"date":175,"type":39},"2025-04-13",{"date":177,"type":39},"2025-03-03",{"date":179,"type":21},"2027-06-03",{"name":157,"class":131},{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":187,"enrollmentInfo":188,"targetDuration":4,"studyType":22,"phases":190,"briefSummary":191,"conditions":192,"keywords":194,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":158},"100560283","phase-2-modified-folfoxiri-plus-target-therapy-as-a-first-line-treatment-for-advanced-colorectal-cancer-a-prospective-phase-two-study-100560283","NCT06575127","Modified FOLFOXIRI Plus Target Therapy as a First Line Treatment for Advanced Colorectal Cancer a Prospective Phase Two Study","Inclusion Criteria:\n\nHistologically confirmed unrespectable or metastatic colorectal cancer with or without primary tumor in situ.\n\n* Patients were required to have measurable disease according to RECIST v1.1 (Response Evaluation Criteria in Solid Tumors) (Eisenhauer EA,2009)\n* ECOG PS 0-1 better to exclude PS II as this protocol is known to be toxic\n* Adequate baseline hematology and clinical chemistry labs\n* Adequate cardiac function\n\nExclusion Criteria:\n\n* Double Malignancy\n* DPYD mutant patients\n* Peripheral neuropathy grade 3 or higher patient due to other comorbidities\n* Inflammatory bowel syndrome or any other chronic GIT disease\n* Prior exposure to chemotherapy treatment for colorectal cancer in the metastatic setting\n* Patients who have contraindications for one or more of the study protocol drugs","65 Years",{"count":189,"type":21},60,[24],"This prospective Phase II study aims to evaluate the efficacy and safety of a modified FOLFOXIRI regimen in the treatment of metastatic colorectal cancer (MCRC). FOLFOXIRI, though effective, is known for its high toxicity, necessitating close monitoring and dose adjustments. .\n\nThe primary endpoint is to assess the impact on the objective response rate and evaluate both acute and delayed toxicity. The secondary endpoints include studying the treatment's effectiveness as conversion therapy, along with disease-free survival (DFS) and overall survival (OS). The tertiary endpoint focuses on evaluating predictive and prognostic factors of significance.\n\nThis study seeks to balance the efficacy of FOLFOXIRI with a modified dose to minimize toxicity while maintaining therapeutic benefits, providing a potentially safer and effective option for patients with MCRC.",[27,193],"Colon Cancer Stage 4",[195,196,197],"Colon Cancer","MCRC","FOLFOXIRI","2024-08-26",{"date":200,"type":39},"2024-08-28",{"date":202,"type":39},"2024-08-17",{"date":204,"type":21},"2026-09-01",{"name":206,"class":131},"Al-Azhar University",{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":211,"acronym":212,"eligibilityCriteria":213,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":214,"targetDuration":4,"studyType":216,"phases":4,"briefSummary":217,"conditions":218,"keywords":221,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":158},"100352761","body-mass-index-bmi-and-quality-of-life-qol-in-cancer-patients-100352761","NCT03873064","Body Mass Index (BMI) and Quality of Life (QoL) in Cancer Patients","BMI-QoL","Inclusion Criteria:\n\n1. Histologically confirmed diagnosis of solid tumor\n2. Age \\>18 years\n3. Signed informed consent\n4. Life expectancy \\> 12 weeks\n\nExclusion Criteria:\n\n1. Inability to fill out the EORTC QLQ-C30 questionnaire.\n2. Absence of a certain diagnosis of solid tumor (e.g. subjects on screening programs)\n3. Diagnosis of second malignancies that might bias results interpretation",{"count":215,"type":21},1380,"OBSERVATIONAL","BMI is a simple and widely recorded variable that may capture obesity or cachexia in cancer patients. How BMI is associated to health-related quality of life (HR-QoL) in such patients is poorly investigated.\n\nHigh BMI may be associated to obesity, an increased burden of comorbidity, reduced physical activity and, in some settings, to more aggressive oncological disease. On the other hand, low BMI may reflect enhanced weight loss, cachectic syndrome, higher tumor burden and adverse prognostic features which all deteriorate quality of life. The aim of the present study is to evaluate the association of BMI and HR-QoL as measured by the EORTC-QLQ-C30 questionnaire in several cancer settings (such as localized vs metastatic or distinct primary tumors).",[27,219,220],"Body Weight","Quality of Life",[222,223,224,225],"BMI","EORTC QLQ-C30","metastatic cancer","localized cancer","2024-02-01",{"date":228,"type":39},"2024-02-02",{"date":230,"type":39},"2019-01-15",{"date":232,"type":21},"2034-01-15",{"name":234,"class":131},"University of Rome Tor Vergata",{"id":236,"slug":237,"hasResults":11,"nctId":238,"briefTitle":239,"officialTitle":240,"acronym":241,"eligibilityCriteria":242,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":243,"targetDuration":245,"studyType":216,"phases":4,"briefSummary":246,"conditions":247,"keywords":251,"overallStatus":35,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":259,"completionDateStruct":261,"leadSponsor":263,"locationsCount":158},"100400557","aims-cancer-outcomes-study-100400557","NCT04495790","AIMS Cancer Outcomes Study","Advanced Integrative Oncology Treatment for Adult and Pediatric Patients With Cancer: A Prospective Outcomes Study","ACOS","Inclusion Criteria:\n\n1. A new patient coming in for a first office call (FOC) or first consultation via telemedicine with a diagnosis of cancer, or\n2. An established patient with a diagnosis of cancer receiving treatment at the AIMS Institute;\n3. If over 18 years of age are able to understand study design adequately and provide signed informed consent (IC) to enrollment;\n4. If younger than 18 years of age informed assent from the child and informed consent from a parent or guardian who is able to understand the study design adequately and provide signed informed consent for the pediatric patient;\n5. A confirmed diagnosis of cancer based on medical oncology medical records.\n\nExclusion Criteria:\n\n1. Patients not diagnosed with cancer;\n2. Telehealth patients;\n3. Cannot read or understand English well enough to read and sign the consent form and complete the questionnaires;\n4. Unwilling to participate in the AIMS Institute observational study.",{"count":244,"type":21},500,"5 Years","The overall aim is to describe disease-free survival (DFS) in early stage cancer patients and three-year overall survival (OS) outcomes in advanced stage cancer patients receiving Advanced Integrative Oncology (AIO) treatment in a prospective consecutive case series outcomes study. We will collect data and study outcomes for patients with cancer who receive care at AIMS Institute.",[66,27,248,249,250],"Advanced Cancer","Advanced Solid Tumor","Oncology",[252,253,254,255,113],"Integrative Oncology","Naturopathic Oncology","Phytomedicine","Metabolic Therapy","2023-01-30",{"date":258,"type":39},"2023-02-01",{"date":260,"type":39},"2020-05-18",{"date":262,"type":21},"2030-12-31",{"name":264,"class":131},"Advanced Integrative Medical Science Institute","Neoplasm, Malignant"]